Cargando…
Decreased levels of soluble amyloid β-protein precursor and β-amyloid protein in cerebrospinal fluid of patients with systemic lupus erythematosus
Symptoms originating from the central nervous system (CNS) frequently occur in patients with systemic lupus erythematosus (SLE). These symptoms are extremely diverse, including a state of dementia. The aim of this study was to examine the cerebrospinal fluid (CSF) content of soluble molecules indica...
Autores principales: | Trysberg, Estelle, Höglund, Kina, Svenungsson, Elisabet, Blennow, Kaj, Tarkowski, Andrej |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC400431/ https://www.ncbi.nlm.nih.gov/pubmed/15059276 http://dx.doi.org/10.1186/ar1040 |
Ejemplares similares
-
Intrathecal levels of matrix metalloproteinases in systemic lupus erythematosus with central nervous system engagement
por: Trysberg, Estelle, et al.
Publicado: (2004) -
Heteromers of amyloid precursor protein in cerebrospinal fluid
por: Cuchillo-Ibañez, Inmaculada, et al.
Publicado: (2015) -
Blood‐brain barrier dysfunction and reduced cerebrospinal fluid levels of soluble amyloid precursor protein‐β in patients with subcortical small‐vessel disease
por: Kettunen, Petronella, et al.
Publicado: (2022) -
Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid
por: Selnes, Per, et al.
Publicado: (2010) -
β-site amyloid precursor protein-cleaving
enzyme 1(BACE1) inhibitor treatment induces Aβ5-X peptides through alternative amyloid
precursor protein cleavage
por: Portelius, Erik, et al.
Publicado: (2014)